2. Search Result
Search Result
Results for "

Phosphodiesterase I

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

4

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137592
    Nicotinamide 1,N6-ethenoadenine dinucleotide

    ε-NAD

    		 Fluorescent Dye Phosphodiesterase (PDE) Glutamate Dehydrogenase (GLDH) Others
    Nicotinamide 1,N6-ethenoadenine dinucleotide (ε-NAD) is a fluorescent analog of NAD. Nicotinamide 1,N6-ethenoadenine dinucleotide can be cleaved by phosphodiesterase I (from C. adamanteus venom) and binds to bovine liver glutamate dehydrogenase. Nicotinamide 1,N6-ethenoadenine dinucleotide can serve as a substrate for G-ADP ribosylation of G proteins catalyzed by bacterial toxins. Nicotinamide 1,N6-ethenoadenine dinucleotide can be used as a fluorescent substrate for the study of ADP ribosylation reactions .
    Nicotinamide 1,N6-ethenoadenine dinucleotide
  • HY-134124
    Glutathione ethyl ester

    		Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-13295
    Vinpocetine
    5+ Cited Publications

    Ethyl apovincaminate

    		 Sodium Channel IKK Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na + channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .
    Vinpocetine
  • HY-100530D
    Rp-cAMPS sodium salt
    5 Publications Verification

    		 PKA Neurological Disease
    Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS sodium salt
  • HY-P2878
    Phosphodiesterase I
    1 Publications Verification

    PDE

    		 Phosphodiesterase (PDE) Neurological Disease Cancer
    Phosphodiesterase I (PDE) is an enzyme that can catalyze the hydrolysis of the 3' ring phosphate bond of cyclic nucleotides, and is often used in biochemical research. Phosphodiesterase I acts as an important regulator of signal transduction mediated by the second messenger molecules cAMP and cGMP. According to their specificity to cyclic nucleotides, they can also be divided into different types, such as PDE1-PDE11, which also have certain potential in various diseases .
    Phosphodiesterase I
  • HY-N2038
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone

    		Phosphodiesterase (PDE) Neurological Disease Cancer
    3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma .
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone
  • HY-100530C
    Sp-cAMPS sodium salt

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-W273690
    Pentifylline

    1-Hexyltheobromine; Hexyltheobromine

    		 Drug Intermediate Collagen Cardiovascular Disease Neurological Disease
    Pentifylline (1-Hexyltheobromine; Hexyltheobromine), PTX (HY-B0715) precursor compound, is a vasodilator. Pentifylline decreases procollagen levels and inhibits collagen production. Pentifylline reduces functional nuclear NF-1 to suppress procollagen gene transcription .
    Pentifylline
  • HY-100530A
    Rp-cAMPS

    		PKA Neurological Disease
    Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS
  • HY-100530
    Rp-cAMPS triethylammonium salt
    5 Publications Verification

    		 PKA Neurological Disease
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS triethylammonium salt
  • HY-108621
    RS-25344 hydrochloride

    		Phosphodiesterase (PDE) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects .
    RS-25344 hydrochloride
  • HY-13295R
    Vinpocetine (Standard)

    Ethyl apovincaminate (Standard)

    		 Reference Standards Sodium Channel IKK Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na + channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .
    Vinpocetine (Standard)
  • HY-P2878A
    Phosphodiesterase l, Rattlesnake venom

    PDE, Rattlesnake venom

    		 Phosphodiesterase (PDE) Metabolic Disease
    Phosphodiesterase l, Rattlesnake venom (PDE, Rattlesnake venom) is a non-selective phosphodiester bond hydrolase targeting phosphodiester bonds in oligonucleotides, catalyzing their hydrolysis into mononucleotides. Phosphodiesterase l, Rattlesnake venom cleaves phosphodiester linkages in DNA fragments digested by DNase I. Phosphodiesterase l, Rattlesnake venom is promising for research of nucleic acid structure and metabolism .
    Phosphodiesterase l, Rattlesnake venom
  • HY-114303
    CM-675

    		Phosphodiesterase (PDE) HDAC Neurological Disease
    CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease .
    CM-675
  • HY-137108
    Sp-8-pCPT-cGMPS

    		PKA PKG Neurological Disease
    Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .
    Sp-8-pCPT-cGMPS
  • HY-100530B
    Sp-cAMPS

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-110005
    Sp-cAMPS triethylamine

    		PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-159857
    Gp(2′-5′)Ap sodium

    Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    		 Nucleoside Antimetabolite/Analog
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-P2424
    Cholecystokinin-J

    CCK-J

    		 Calcium Channel Others
    Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
    Cholecystokinin-J
  • HY-134302
    8-HA-cAMP

    8-Hexylamino-cAMP

    		 PKA Others
    8-HA-cAMP is a membrane-permeable cAMP analogue and an activator of cAMP-dependent protein kinase and PKA I. 8-HA-cAMP exerts metabolic stability towards mammalian cyclic nucleotide-responsive phosphodiesterases .
    8-HA-cAMP
  • HY-131764
    2'-O-MB-cGMP sodium

    2′-O-Monobutyryl-cGMP sodium

    		 Phosphodiesterase (PDE) Others
    2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I50 value of 35 µM. 2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium inhibits Ca 2+ dependent phosphodiesterase hydrolysis using cAMP or cGMP as substrate .
    2'-O-MB-cGMP sodium
  • HY-P2878B
    Phosphodiesterase I, Bothrops atrox

    		Biochemical Assay Reagents Metabolic Disease
    Phosphodiesterase I, Bothrops atrox (EC 3.1.4.1) breaks phosphodiester bonds and catalyzes the hydrolysis of various nucleotide polyphosphates. Phosphodiesterase I is released from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C.
    Phosphodiesterase I, Bothrops atrox
  • HY-106098
    Adibendan

    BM 14478

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Adibendan (BM 14478), a benzimidazole derivative, is an orally active, selective phosphodiesterase III (PDE III) activity inhibitor (IC50=2.0 μM). Adibendan has IC50 values more than 60-fold higher for the inhibition of PDE I or II. Adibendan is a new cardiotonic agent .
    Adibendan
  • HY-137633
    Sp-8-Br-PET-cGMPS

    		PKG Neurological Disease
    Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .
    Sp-8-Br-PET-cGMPS
  • HY-P2878C
    Phosphodiesterase I, Crotalus atrox (Western Diamondback Rattlesnake)

    		Biochemical Assay Reagents Metabolic Disease
    Phosphodiesterase I, Crotalus atrox (Western Diamondback Rattlesnake) (EC 3.1.4.1) breaks phosphodiester bonds and catalyzes the hydrolysis of various nucleotide polyphosphates. Phosphodiesterase I is released from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C.
    Phosphodiesterase I, Crotalus atrox (Western Diamondback Rattlesnake)
  • HY-13295S
    Vinpocetine-d5

    		Isotope-Labeled Compounds Sodium Channel IKK Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .
    Vinpocetine-d5
  • HY-N2038R
    3,?5,?6,?7,?8,?3',?4'-?Heptemthoxyflavone (Standard)

    		Reference Standards Phosphodiesterase (PDE) Neurological Disease Cancer
    3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (Standard) is the analytical standard of 3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone (HY-N2038). This product is intended for research and analytical applications. 3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma .
    3,?5,?6,?7,?8,?3',?4'-?Heptemthoxyflavone (Standard)
  • HY-100530CR
    Sp-cAMPS sodium salt (Standard)

    		PKA Reference Standards Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS (sodium salt) (Standard) is the analytical standard of Sp-cAMPS (sodium salt) (HY-100530C). This product is intended for research and analytical applications. Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt (Standard)
  • HY-108621R
    RS-25344 hydrochloride (Standard)

    		Reference Standards Phosphodiesterase (PDE) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    RS-25344 hydrochloride (Standard) is the analytical standard of RS-25344 (hydrochloride) (HY-108621). This product is intended for research and analytical applications. RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects .
    RS-25344 hydrochloride (Standard)
  • HY-DY1108
    Nicotinamide 1,N6-ethenoadenine dinucleotide (solution)

    ε-NAD (solution)

    		 Glutamate Dehydrogenase (GLDH) Phosphodiesterase (PDE) Fluorescent Dye Others
    Nicotinamide 1,N6-ethenoadenine dinucleotide (solution) (ε-NAD (solution)) is a fluorescent analog of NAD. Nicotinamide 1,N6-ethenoadenine dinucleotide can be cleaved by phosphodiesterase I (from C. adamanteus venom) and binds to bovine liver glutamate dehydrogenase. Nicotinamide 1,N6-ethenoadenine dinucleotide can serve as a substrate for G-ADP ribosylation of G proteins catalyzed by bacterial toxins. Nicotinamide 1,N6-ethenoadenine dinucleotide can be used as a fluorescent substrate for the study of ADP ribosylation reactions .
    Solvent and concentration: ddH2O: 20 mM
    Nicotinamide 1,N6-ethenoadenine dinucleotide (solution)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: